Pradaxa is a prescription blood thinner used to prevent and treat blood clots. Its most common use is reducing the risk of stroke in people with atrial fibrillation, a type of irregular heartbeat. It is also prescribed to treat blood clots in the legs and lungs, prevent those clots from coming back, and protect against clots after hip replacement surgery.
Approved Uses of Pradaxa
Pradaxa (the brand name for dabigatran etexilate) has four FDA-approved uses in adults:
- Stroke prevention in atrial fibrillation. People with non-valvular atrial fibrillation have blood that can pool in the heart’s upper chambers, forming clots that travel to the brain. Pradaxa reduces this risk.
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). These are blood clots in the deep veins of the legs or clots that have traveled to the lungs. Pradaxa is used after an initial 5 to 10 days of injectable blood thinners.
- Prevention of recurring DVT and PE. For people who have already been treated for a blood clot, Pradaxa helps keep it from happening again.
- Clot prevention after hip replacement. Hip surgery significantly raises the risk of blood clots forming in the legs, and Pradaxa is used as a preventive measure during recovery.
Pradaxa is also approved for children ages 3 months through 17 years for the treatment of blood clots and the prevention of recurrence, again after an initial course of injectable blood thinners.
How Pradaxa Prevents Clots
Pradaxa works by directly blocking thrombin, a protein that sits at the final step of the clotting process. Thrombin’s job is to convert a substance called fibrinogen into fibrin, the mesh-like material that holds a blood clot together. By blocking thrombin’s active site, Pradaxa stops fibrin from forming, prevents clots from being reinforced and cross-linked, and reduces the chain reaction that amplifies clotting.
What makes Pradaxa different from older blood thinners like warfarin is its directness. Warfarin works upstream, interfering with the production of several clotting factors through vitamin K. Pradaxa targets thrombin itself, both when it’s floating freely in the blood and when it’s already bound to a forming clot. This means it can inhibit clot growth even after the process has started.
Who Should Not Take Pradaxa
Pradaxa is specifically contraindicated in people with mechanical (prosthetic) heart valves. A clinical trial called RE-ALIGN tested Pradaxa against warfarin in 252 patients with mechanical valve replacements and found higher rates of both blood clots and bleeding in the Pradaxa group, regardless of how long ago the valve was implanted. The trial was stopped early because of these results. People with mechanical heart valves need warfarin or another anticoagulant instead.
Kidney function also plays a major role in whether Pradaxa is appropriate. The drug is cleared from the body largely through the kidneys, so reduced kidney function causes it to build up in the bloodstream, raising the risk of bleeding. People with severe kidney impairment take a lower dose, and for those with very poor kidney function or on dialysis, there isn’t enough data to recommend a safe dose at all. Your doctor will check your kidney function before starting Pradaxa and periodically afterward.
What Treatment Looks Like
For atrial fibrillation, the standard dose is 150 mg taken twice daily, with or without food. People with reduced kidney function may take 75 mg twice daily instead. Unlike warfarin, Pradaxa does not require regular blood tests to monitor clotting levels, and it has fewer dietary restrictions since it doesn’t interact with vitamin K in food.
For blood clots in the legs or lungs, you won’t start on Pradaxa right away. You’ll first receive an injectable blood thinner for 5 to 10 days, typically in a hospital or clinic setting. Once that initial treatment period is complete, you transition to Pradaxa capsules at 150 mg twice daily. This two-step approach is required because Pradaxa alone isn’t effective at managing the acute, early phase of a serious clot.
Bleeding Risk and Emergency Reversal
Like all blood thinners, Pradaxa’s primary risk is bleeding. Minor bleeding such as nosebleeds, bruising, or bleeding gums is relatively common. More serious bleeding, while less frequent, can occur in the stomach, intestines, or brain.
One significant advantage Pradaxa has over some other blood thinners is that it has a specific reversal agent called Praxbind (idarucizumab). If you experience life-threatening bleeding or need emergency surgery while on Pradaxa, this reversal agent can be given intravenously to neutralize the drug’s effects rapidly. Not all blood thinners have a dedicated antidote, which makes this an important safety consideration when choosing an anticoagulant.
Stopping Before Surgery
If you’re scheduled for an elective surgery or procedure, you’ll need to stop taking Pradaxa ahead of time. How far in advance depends on two things: your kidney function and how high the bleeding risk of the procedure is.
For people with normal kidney function undergoing a standard-risk procedure, the last dose is typically taken the morning before surgery (about 24 hours ahead). For high-risk surgeries like cardiac, neurological, or major abdominal operations, you’ll stop two days before. If your kidneys don’t clear the drug as efficiently, the timeline stretches further. People with moderately reduced kidney function may need to stop two to four days before, depending on the procedure.
Storing Pradaxa Properly
Pradaxa capsules are unusually sensitive to moisture, which can cause them to break down and lose effectiveness. Keep them in the original bottle or blister packaging at all times. If your prescription comes in a bottle, keep it tightly closed and use the capsules within four months of first opening it. Don’t transfer capsules into a weekly pill organizer, as even brief exposure to humidity can degrade them.